ClinicalTrials.gg
CompletedNCT07946718Updated Nov 18, 2026

Effects of Ozonated Oil Eye Drops on the Ocular Surface and Inflammation in Women

An interventional study of Liposomal Ozonated Oil Ophthalmic Gel in Dry Eye Disease (DED), sponsored by University of Seville. Completed at 1 site in Spain. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Seville · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Apr 2025, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 44 studies in Dry Eye Syndromes with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · Spain.

Enrollment
34th of 41
27 · median 60
Started
2025
with 3 others
No phase
21 of 44
1 open now
Registered
44th of 44
by date
Lead sponsor
6 of 44
University of Seville

Among the 44 studies in Dry Eye Syndromes with a site in Spain, this one is the 34th largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2025, is one of 21 with no phase, and was the 44th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 44 studies in Dry Eye Syndromes with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Dry Eye Syndromes with a site in Spain, or all of them as a file.
02

Study summary

This study examines the effects of an eye gel containing liposomal ozonated oil in middle-aged women with dry eye disease. Dry eye can cause discomfort, an unstable tear film, and inflammation of the eye surface.

The main questions are whether one week of treatment changes:

Tear film stability and other signs and symptoms of dry eye.

Markers of inflammation in cells collected from the eye surface.

Proteins involved in maintaining connections between eye surface cells.

Women with dry eye use the eye gel for one week and undergo assessments before and after treatment. These assessments include a symptom questionnaire, eye surface examinations, and collection of small samples of cells from the conjunctiva, the thin tissue covering the white of the eye.

A separate group of healthy young women undergoes one assessment without receiving treatment. Their measurements provide reference values for comparison with those of women with dry eye.

Read the detailed description

This prospective, nonrandomized interventional study combines a before-and-after treatment assessment in women with dry eye disease with a separate healthy reference group.

Women aged 45-65 years with dry eye disease receive a commercially available ophthalmic gel containing liposomal ozonated oil, hydroxyethylcellulose, and poloxamer 407 for one week. Clinical assessments and conjunctival impression cytology are performed at baseline and after treatment. Healthy women aged 18-30 years undergo a single assessment without treatment.

Conjunctival samples are examined using quantitative real-time PCR to assess the expression of inflammatory cytokines, matrix metalloproteinases, and MUC5AC. Immunofluorescence analysis of ZO-1 and E-cadherin is used to examine epithelial junctional organization and cell morphology.

Treatment-associated changes are assessed within the dry eye group. The healthy group provides a biological reference and does not serve as a randomized treatment comparator.

03

Conditions studied

  • Dry Eye Disease (DED)

Browse trials for

Keywords

  • dry eye
  • ozonated oil
  • Liposomal Ozonated Oil
  • Ocular Surface Inflammation
  • Conjunctival Impression Cytology
  • Inflammatory Cytokines
  • Matrix Metalloproteinases
  • MUC5AC
  • Epithelial Junctions
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Dry Eye Disease Group:

  • Female participants aged 45-65 years.
  • Six-item Ocular Surface Disease Index (OSDI-6) score greater than 4.
  • Non-invasive tear break-up time (NIBUT) less than 10 seconds.
  • Written provided before participation.

Healthy Reference Group:

  • Healthy female participants aged 18-30 years without dry eye disease.
  • Six-item Ocular Surface Disease Index (OSDI-6) score less than 4.
  • Non-invasive tear break-up time (NIBUT) of at least 10 seconds.
  • Written informed consent provided before participation.

Exclusion criteria

Exclusion Criteria for Both Groups:

  • Previous ocular surgery.
  • Active ocular infection.
  • Current use of topical or systemic medication with potential effects on the tear film or ocular surface.
  • Concomitant medication that could interfere with study outcomes.
  • Pregnancy or breastfeeding.
  • Any ocular or systemic condition that, in the investigators' opinion, could interfere with study procedures or interpretation of clinical or molecular outcomes.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Dry Eye Treatment Group

    Women aged 45-65 years with dry eye disease receive liposomal ozonated oil ophthalmic gel for one week. Clinical ocular surface assessments and conjunctival impression cytology are performed before and after treatment.

    Device: Liposomal Ozonated Oil Ophthalmic Gel

  • No intervention
    Healthy Reference Group

    Healthy women aged 18-30 years without dry eye disease receive no study treatment and undergo a single clinical ocular surface assessment and conjunctival impression cytology. This group provides biological reference values.

Interventions

  • DeviceLiposomal Ozonated Oil Ophthalmic Gel

    Topical ophthalmic administration of a sterile gel containing liposomal ozonated oil, hydroxyethylcellulose, and poloxamer 407 (OZONEST Gel-K). Participants instill one drop into each eye three times daily for seven consecutive days.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in First Non-Invasive Tear Break-Up Time

    Change in first non-invasive tear break-up time (F-NIBUT), measured in seconds using an ocular surface analyzer, in participants with dry eye disease. F-NIBUT is the time between a complete blink and the first detected disruption of the tear film. Longer values indicate greater tear film stability.

    Time frame: Baseline and Day 7

  2. Change From Baseline in Conjunctival IL1B mRNA Expression

    Change from baseline to Day 7 in relative IL1B mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.

    Time frame: Baseline and Day 7

  3. Change From Baseline in Conjunctival IL6 mRNA Expression

    Change from baseline to Day 7 in relative IL6 mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.

    Time frame: Baseline and Day 7

  4. Change From Baseline in Conjunctival IL10 mRNA Expression

    Change from baseline to Day 7 in relative IL10 mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.

    Time frame: Baseline and Day 7

  5. Change From Baseline in Conjunctival TNF mRNA Expression

    Change from baseline to Day 7 in relative TNF mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.

    Time frame: Baseline and Day 7

  6. Change From Baseline in Conjunctival MMP1 mRNA Expression

    Change from baseline to Day 7 in relative MMP1 mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.

    Time frame: Baseline and Day 7

  7. Change From Baseline in Conjunctival MMP3 mRNA Expression

    Change from baseline to Day 7 in relative MMP3 mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.

    Time frame: Baseline and Day 7

  8. Change From Baseline in Conjunctival MMP9 mRNA Expression

    Change from baseline to Day 7 in relative MMP9 mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.

    Time frame: Baseline and Day 7

  9. Change From Baseline in Conjunctival MUC5AC mRNA Expression

    Change from baseline to Day 7 in relative MUC5AC mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.

    Time frame: Baseline and Day 7

07

Study locations

1 site
  • Optometry and Contactology Clinic, Faculty of Pharmacy, University of Seville
    Seville, Andalusia 41012, Spain
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Sep 2026, 17 months.

Of 200 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's 17 months is above that.

Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Apr 1, 2025
Primary completionActual
Sep 30, 2026
CompletionActual
Sep 30, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946718
Collaborators
Esteve Pharmaceuticals, S.A.
Responsible party
José-María Sánchez-González (OD PhD, University of Seville) — Principal investigator
First posted
Nov 18, 2026
Start date
Apr 1, 2025
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion